Free Trial

Maravai LifeSciences Q4 2022 Earnings Report

Maravai LifeSciences logo
$5.58 -0.22 (-3.79%)
(As of 05:44 PM ET)

Maravai LifeSciences EPS Results

Actual EPS
$0.35
Consensus EPS
$0.34
Beat/Miss
Beat by +$0.01
One Year Ago EPS
$0.45

Maravai LifeSciences Revenue Results

Actual Revenue
$204.70 million
Expected Revenue
$204.95 million
Beat/Miss
Missed by -$250.00 thousand
YoY Revenue Growth
-10.40%

Maravai LifeSciences Announcement Details

Quarter
Q4 2022
Time
After Market Closes

Conference Call Resources

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

Maravai LifeSciences Earnings Headlines

Missed Nvidia? Buy Elon Musk’s “Silent Partner”
In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.
See More Maravai LifeSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Maravai LifeSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Maravai LifeSciences and other key companies, straight to your email.

About Maravai LifeSciences

Maravai LifeSciences (NASDAQ:MRVI), a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

View Maravai LifeSciences Profile

More Earnings Resources from MarketBeat

Upcoming Earnings